3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
pembrolizumab
602
Cyclophosphamide
545
Magnetic Resonance Spectroscopy
524
Radiotherapy
513
Specimen Handling
506
Nivolumab
412
Cisplatin
380
Carboplatin
368
Biopsy
306
Blood Specimen Collection
302
Radiosurgery
290
Paclitaxel
280
Surveys and Questionnaires
270
Gemcitabine
270
Standard of Care
267
Drug Therapy
263
Dexamethasone
263
fludarabine
262
Bevacizumab
253
venetoclax
251
Oxaliplatin
209
Capecitabine
201
Rituximab
198
Radiation
192
Fluorouracil
189
Ipilimumab
188
durvalumab
184
Doxorubicin
179
Etoposide
176
atezolizumab
175
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
2019-nCoV Vaccine mRNA-1273
×
1 year
×
Clear all
NCT05556720
2025-10-03
BOOST-IC
Monash University
Phase 3
Active not recruiting
960 enrolled